Sort

Search

08/11/2023 Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden
Santos-García, D, Fonticoba, TD, Bartolomé, CC, Painceiras, MJF, Díaz, IG, Alvarado, MCI, Paz, JM, Jesús, S, Cosgaya, M, Caldentey, JG, Caballol, N, Legarda, I, Vara, JH, Cabo, I, Manzanares, LL, Aramburu, IG, Rivera, MAA, Mayordomo, VG, Nogueira, V, García-Soto, JD, Borrué, C, Vila, BS, Sauco, MA, Vela, L, Escalante, S, Cubo, E, Mendoza, Z, Castrillo, JCM, Alonso, PS, Losada, MGA, Ariztegui, NL, Gastón, I, Kulisevsky, J, Seijo, M, Valero, C, Redondo, RA, Buongiorno, MT, Ordás, C, Menéndez-González, M, Mcafee, D, Martinez-Martin, P, Mir, P, COPPADIS Study Grp. Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden. Brain and Behavior. 2023; 13(12)DOI:10.1002/brb3.3295. PMID:37939322. IF:2.600(Q2/3D).
06/11/2023 Assessment of a venous thromboembolism prophylaxis shared decision-making intervention (DASH-TOP) using the decisional conflict scale: a mixed-method study
León-García, M, Humphries, B, Morales, PR, Gravholt, D, Eckman, MH, Bates, SM, Suarez, NRE, Xie, F, Perestelo-Pérez, L, Alonso-Coello, P. Assessment of a venous thromboembolism prophylaxis shared decision-making intervention (DASH-TOP) using the decisional conflict scale: a mixed-method study. BMC Medical Informatics and Decision Making. 2023; 23(1)DOI:10.1186/s12911-023-02349-3. PMID:37932759. IF:3.300(Q2/5D).
06/11/2023 Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials
Yosipovitch, G, Lio, PA, Rosmarin, D, Serra-Baldrich, E, Legat, FJ, Casillas, M, Pierce, E, Liu, ZQ, Sun, LN, Elmaraghy, H, Ständer, S. Lebrikizumab improved itch and reduced the extent of itch interference on sleep in patients with moderate-to-severe atopic dermatitis: two randomized, placebo-controlled, phase III trials. BRITISH JOURNAL OF DERMATOLOGY. 2023; 190(2)DOI:10.1093/bjd/ljad435. PMID:37939793. IF:11.000(Q1/1D).
06/11/2023 Fulminant myocarditis proven by early biopsy and outcomes
Huang, F, Ammirati, E, Ponnaiah, M, Montero, S, Raimbault, V, Abrams, D, Lebreton, G, Pellegrino, V, Ihle, J, Bottiroli, M, Persichini, R, Barrionuevo-Sánchez, MI, Ariza-Solé, A, Ng, PY, Sin, SWC, Ayer, R, Buscher, H, Belaid, S, Delmas, C, Ferreira, R, Albuquerque, RR Jr, López-Sobrino, T, Bunge, JJH, Fisser, C, Franchineau, G, Mccanny, J, Ohshimo, S, Sionis, A, Hernández-Pérez, FJ, Barge-Caballero, E, Balik, M, Muglia, H, Park, S, Donker, DW, Porral, B, Aïssaoui, N, Dessap, AM, Burgos, V, Lesouhaitier, M, Fried, J, Jung, JS, Rosillo, S, Scherrer, V, Nseir, S, Winszewski, H, Jorge-Pérez, P, Kimmoun, A, Diaz, R, Combes, A, Schmidt, M, FULLMOON Study Grp. Fulminant myocarditis proven by early biopsy and outcomes. EUROPEAN HEART JOURNAL. 2023; 44(48)DOI:10.1093/eurheartj/ehad707. PMID:37941449. IF:38.100(Q1/1D).